Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 2026-09-30			5-day change	1st Jan Change
933.00 ^PKR	-1.08%		-2.73%	-8.75%

08-27	Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	49,433	-	-
Change	-	11.36%	-8.75%	-	-
Enterprise Value (EV)	48,650	54,175	49,433	49,433	49,433
Change	-	11.36%	-8.75%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.63x	1.45x	1.29x
EV / Revenue	-	0x	1.63x	1.45x	1.29x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.82%	5.57%	6.43%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	933.00	933.00	933.00
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	3/26/25	4/7/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.77%	179M
ELI LILLY AND COMPANY	33.68x	12.2x	24.79x	0.59%	1,031B
JOHNSON & JOHNSON	29.76x	6.61x	18.5x	2%	638B
ABBVIE INC.	33.32x	7.79x	16.11x	2.63%	462B
MERCK & CO., INC.	108.6x	6.05x	25.67x	2.29%	359B
ROCHE HOLDING AG	19.01x	4.64x	11.49x	2.87%	335B
NOVARTIS AG	20.51x	5.32x	13.17x	3.01%	273B
ASTRAZENECA PLC	20.92x	4.34x	12.36x	2.04%	253B
AMGEN INC.	26.76x	6.95x	12.37x	2.38%	228B
GILEAD SCIENCES, INC.	-45.76x	6.66x	26x	2.18%	185B
Average	27.42x	6.73x	17.83x	2.47%	376.4B
Weighted average by Cap.	32.67x	7.84x	19.19x	1.9%